Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
May 31, 2025 72.86%
February 28, 2025 81.03%
November 30, 2024 74.18%
August 31, 2024 78.40%
May 31, 2024 77.71%
February 29, 2024 64.29%
November 30, 2023 75.94%
August 31, 2023 72.02%
May 31, 2023 66.72%
February 28, 2023 71.71%
November 30, 2022 68.03%
August 31, 2022 70.46%
May 31, 2022 15.66%
February 28, 2022 61.94%
November 30, 2021 61.91%
August 31, 2021 63.75%
May 31, 2021 61.21%
February 28, 2021 58.68%
November 30, 2020 61.43%
August 31, 2020 49.60%
May 31, 2020 51.82%
February 29, 2020 52.90%
November 30, 2019 53.47%
August 31, 2019 56.07%
May 31, 2019 53.71%
Date Value
February 28, 2019 56.59%
November 30, 2018 62.53%
August 31, 2018 62.11%
May 31, 2018 73.06%
February 28, 2018 74.34%
November 30, 2017 68.27%
August 31, 2017 71.96%
May 31, 2017 74.54%
February 28, 2017 71.79%
November 30, 2016 75.28%
August 31, 2016 75.92%
May 31, 2016 76.13%
February 29, 2016 78.34%
November 30, 2015 81.58%
August 31, 2015 80.56%
May 31, 2015 80.96%
February 28, 2015 76.02%
November 30, 2014 61.06%
August 31, 2014 -16.00K%
May 31, 2014 93.40%
February 28, 2014 2.81%
November 30, 2013 7.30%
August 31, 2013 62.20%
May 31, 2013 54.31%
February 28, 2013 62.87%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Spectral Medical, Inc. -186.3%
Resverlogix Corp. --
COSCIENS Biopharma, Inc. 55.27%
Restart Life Sciences Corp. -213.3%
Defence Therapeutics Inc --